Wells Fargo initiated coverage of Kyverna Therapeutics with an Overweight rating and $44 price target. The firm believes CAR T cell therapy for autoimmune disease is still in its early innings, but data are highly compelling with the potential for functional cures in some patients. For Kyverna’s shares, Wells sees upside on multiple internal/external catalysts in 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KYTX:
- Kyverna Therapeutics Launches IPO and Restructures Governance
- Opening Day: Gilead-backed Kyverna overshoots raised IPO expectations
- Kyverna Therapeutics opens at $34.25, IPO priced at $22
- Kyverna Therapeutics indicated to open at $29, IPO priced at $22
- Kyverna Therapeutics indicated to open at $31, IPO priced at $22